Evergreen Capital Management’s West Pharmaceutical WST Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$419K Buy
1,131
+28
+3% +$9.9K 0.01% 971
2026
Q2
$396K Buy
1,103
+129
+13% +$39.4K 0.01% 1044
2026
Q1
$244K Buy
+974
New +$242K 0.01% 1268
2023
Q3
– Sell
-766
Closed -$293K – 851
2023
Q2
$293K Buy
+766
New +$274K 0.01% 566
2020
Q2
– Sell
-1,410
Closed -$215K – 436
2020
Q1
$215K Sell
1,410
-3,518
-71% -$541K 0.02% 321
2019
Q4
$741K Hold
4,928
– – 0.06% 194
2019
Q3
$699K Hold
4,928
– – 0.07% 185
2019
Q2
$617K Hold
4,928
– – 0.06% 201
2019
Q1
$543K Sell
4,928
-83
-2% -$8.63K 0.05% 206
2018
Q4
$491K Buy
5,011
+71
+1% +$7.7K 0.05% 210
2018
Q3
$610K Buy
4,940
+37
+0.8% +$4.15K 0.05% 206
2018
Q2
$487K Buy
4,903
+56
+1% +$5.16K 0.05% 219
2018
Q1
$428K Buy
+4,847
New +$453K 0.04% 213

Other funds holding WST

Evergreen Capital Management's WST Position: Q3 2026 in Review

Evergreen Capital Management increased its West Pharmaceutical (WST) stake by 2.5% in Q3 2026, buying an estimated $9.9K and bringing the position to 1,131 shares worth $419K. The position accounts for 0.01% of the portfolio, ranked #971.

Evergreen Capital Management first reported a position in WST in Q1 2018 and has held it in 13 quarters since. The position peaked at $741K in Q4 2019. 877 funds tracked by Wall St. Rank hold WST as of Q3 2026.

  • Evergreen Capital Management held 1,131 shares of West Pharmaceutical worth $419K as of Q3 2026.
  • Evergreen Capital Management bought 28 West Pharmaceutical shares in Q3 2026, an estimated $9.9K.
  • West Pharmaceutical made up 0.01% of Evergreen Capital Management's portfolio in Q3 2026, its #971 holding.
  • Evergreen Capital Management first reported a position in West Pharmaceutical in Q1 2018 and has held it in 13 quarters since.
  • Evergreen Capital Management's West Pharmaceutical position peaked at $741K in Q4 2019.
  • 877 funds tracked by Wall St. Rank held West Pharmaceutical as of Q3 2026.

Based on Evergreen Capital Management's 13F filing for Q3 2026, filed 23 Oct 2026.